


## Felbamate hydrate

Cat. No.:	HY-B0184A
CAS No.:	1177501-39-1
Molecular Formula:	C <sub>11</sub> H <sub>16</sub> N <sub>2</sub> O <sub>5</sub>
Molecular Weight:	256.26
Target:	iGluR
Pathway:	Membrane Transporter/Ion Channel; Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	Felbamate hydrate (W-554 hydrate) is a potent non-sedative anticonvulsant whose clinical effect may be related to the inhibition of N-methyl-D-aspartate (NMDA).
<b>IC<sub>50</sub> &amp; Target</b>	NMDA Receptor <sup>[1]</sup> .
<b>In Vitro</b>	Felbamate hydrate (W-554 hydrate) is an anti-epileptic drug used in the treatment of epilepsy. It is used to treat partial seizures (with and without generalization) in adults and partial and generalized seizures associated with Lennox-Gastaut syndrome in children. However, an increased risk of potentially fatal aplastic anemia and/or liver failure limit the drug's usage to severe refractory epilepsy <sup>[1]</sup> . Felbamate (W-554) has been proposed to have a unique dual mechanism of action as a positive modulator of GABA <sub>A</sub> receptors and as a blocker of NMDA receptors, particularly isoforms containing the NR2B subunit. Although it is clear that felbamate does cause pharmacological inhibition of NMDA receptors, the relevance of NMDA receptor blockade as a strategy for the treatment of human epilepsy has been questioned. Therefore, the importance of the effects of felbamate on NMDA receptors to its therapeutic action in epilepsy is uncertain <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

- [1]. Kuo CC, et al. Use-dependent inhibition of the N-methyl-D-aspartate currents by felbamate: a gating modifier with selective binding to the desensitized channels. *Mol Pharmacol.* 2004 Feb;65(2):370-80.
- [2]. Harty TP, et al. Felbamate block of recombinant N-methyl-D-aspartate receptors: selectivity for the NR2B subunit. *Epilepsy Res.* 2000 Mar;39(1):47-55.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA